Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults.

35 in total

1. Torsades de pointe probably related to sparfloxacin.

Authors: H Dupont; J F Timsit; B Souweine; B Gachot; M Wolff; B Regnier
Journal: Eur J Clin Microbiol Infect Dis Date: 1996-04 Impact factor: 3.267

2. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group.

Authors: A Ortqvist; M Valtonen; O Cars; M Wahl; P Saikku; C Jean
Journal: Chest Date: 1996-12 Impact factor: 9.410

3. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.

Authors: J A Hoogkamp-Korstanje; S I Dirks-Go; P Kabel; W L Manson; E E Stobberingh; R W Vreede; B I Davies
Journal: J Antimicrob Chemother Date: 1997-03 Impact factor: 5.790

4. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

Authors: D K Chen; A McGeer; J C de Azavedo; D E Low
Journal: N Engl J Med Date: 1999-07-22 Impact factor: 91.245

5. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.

Authors: X S Pan; L M Fisher
Journal: Antimicrob Agents Chemother Date: 1997-02 Impact factor: 5.191

6. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.

Authors: M J Fine; M A Smith; C A Carson; S S Mutha; S S Sankey; L A Weissfeld; W N Kapoor
Journal: JAMA Date: 1996-01-10 Impact factor: 56.272

7. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study.

Authors: L Allegra; N Konietzko; P Leophonte; J Hosie; R Pauwels; J N Guyen; P Petitpretz
Journal: J Antimicrob Chemother Date: 1996-05 Impact factor: 5.790

8. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group.

Authors: H Portier; T May; A Proust
Journal: J Antimicrob Chemother Date: 1996-05 Impact factor: 5.790

9. Community acquired pneumonia in adults: a study comparing clinical features and outcome in Africa (Republic of Guinea) and Europe (France).

Authors: O Sow; M Frechet; A A Diallo; S Soumah; M K Conde; P Diot; E Boissinot; E Lemarié
Journal: Thorax Date: 1996-04 Impact factor: 9.139

10. Safety profile of sparfloxacin in the treatment of respiratory tract infections.

Authors: E Rubinstein
Journal: J Antimicrob Chemother Date: 1996-05 Impact factor: 5.790

The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults.

1. Torsades de pointe probably related to sparfloxacin.

2. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group.

3. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.

4. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

5. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.

6. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.

7. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study.

8. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group.

9. Community acquired pneumonia in adults: a study comparing clinical features and outcome in Africa (Republic of Guinea) and Europe (France).

10. Safety profile of sparfloxacin in the treatment of respiratory tract infections.

1. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

2. Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health.

Review 3. Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones?

4. Quinolone-associated tendonitis: a potential problem in COPD?

5. Pandemic flu. Clinical management of patients with an influenza-like illness during an influenza pandemic.